Linking Brain Arteriovenous Malformations With Anorectal Hemorrhoids: A Clinical and Anatomical Review

JOSHUA A. CUOCO,1 CHRISTOPHER L. HOEHMANN,2 KYLE HITSCHERICH,1 SHERRY M. ZAKHARY,3 JOERG R. LEHESTE,1 AND GERMAN TORRES 1*

1Department of Biomedical Sciences, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York
2Department of Anatomy, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, New York
3Department of Radiology, Brookhaven Memorial Hospital Medical Center, Patchogue, New York

ABSTRACT

Patients who harbor brain arteriovenous malformations are at risk for intracranial hemorrhage. These malformations are often seen in inherited vascular diseases such as hereditary hemorrhagic telangiectasia. However, malformations within the brain also sporadically occur without a hereditary-coding component. Here, we review recent insights into the pathophysiology of arteriovenous malformations, in particular, certain signaling pathways that might underlie endothelial cell pathology. To better interpret the origins, determinants and consequences of brain arteriovenous malformations, we present a clinical case to illustrate the phenotypic landscape of the disease. We also propose that brain arteriovenous malformations might share certain signaling dimensions with those of anorectal hemorrhoids. This working hypothesis provides casual anchors from which to understand vascular diseases characterized by arteriovenous lesions with a hemorrhagic- or bleeding-risk component. Anat Rec, 00:000–000, 2017. © The Authors. The Anatomical Record published by Wiley Periodicals, Inc. on behalf of American Association of Anatomists.

Key words: vascular dysmorphogenesis; hereditary hemorrhagic telangiectasia; intracranial hemorrhage; magnetic resonance imaging; nutritional substances

The anatomical architecture of brain arteriovenous malformations (BAVMs) consists of tangles of aberrant arterial and venous vessels in the brain (Fig. 1A,B). The clustering mass of blood vessels that emerge from this particular vascular anomaly is known as a nidus, an endothelial lesion which often presents with intracranial hemorrhage (ICH). Though relatively uncommon (<1% in the general population), BAVMs represent a significant cause of morbidity due to the high incidence of ICH (Fullerton et al., 2005; Friedlander, 2007; Moht et al., 2013).

Currently, there are few therapeutic options that can be administered to control the neurological symptoms associated with BAVMs (Van Beijnum et al., 2007; Macellari et al., 2014). Furthermore, there are no FDA-approved...
ral hematomas, BAVMs are not associated with cranial pathologies such as arteriovenous fistulas or epidural hematomas. BAVMs are known to be associated with vascular diseases, such as hereditary hemorrhagic telangiectasia (HHT) and sporadic vascular malformations that cause hemorrhagic strokes and epileptic seizures in young patients (Gross et al., 2012; Ieva et al., 2015; Macellari et al., 2014; Zhou et al., 2016). The fact that most cases of BAVMs are sporadic (≥95%) rather than familial suggests (i) de novo coding mutations that arise in gametes, (ii) single-nucleotide polymorphisms (SNPs) with low penetrance or (iii) rare protein-disrupting mutations might contribute to disorders characterized by the abnormal alignment of endothelial cells. These suggestions blur not only BAVMs origins but also variability of syndromes between patients harboring different forms of somatic mutations. From this perspective, BAVMs are a collection of rare conditions with extensive behavioral heterogeneity and whose symptoms are resistant to specific therapies. This is particularly true for the brain's microvasculature, which is poorly understood at the molecular level, with numerous signaling pathways coordinating early endothelial cell growth, differentiation and proliferation (Zhou et al., 2015, 2016). Finally, it should be noted that at the whole-genome scale, each patient has millions of native intronic variants (Baralle and Baralle, 2005). Many of these variants or haplotypes do not code for proteins but instead regulate gene activity, so they can still contribute to the formation of a high-flow nidus.

Regardless of rates, spectrum and determinants of genomic mutations, BAVMs share common susceptibility loci with HHT. HHT, also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder characterized by the presence of vascular malformations in the skin, lung, liver and brain (Gross et al., 2012; Mohl et al., 2013; Goyal et al., 2014; Ieva et al., 2015). Two primary clinical subtypes of HHT are currently clustered. Both subtypes exhibit loss-of-function mutations in genes encoding segments of the transforming growth factor-β (TGF-β) signaling pathway (Fig. 2). For instance, HHT-1 exhibits mutations in endoglin (ENG), which codes for an accessory protein of the TGF-β adaptor complex (Gross et al., 2012; Goyal et al., 2014; Sahlein et al., 2014; Ieva et al., 2015), whereas HHT-2 presents with mutations in activin-like kinase 1 (ALK-1), which codes for a transmembrane-bound kinase receptor associated with the transmission signature of TGF-β (Gross et al., 2012; Goyal et al., 2014; Sahlein et al., 2014; Ieva et al., 2015). TGF-β is a cytokine regulating critical developmental milestones such as cell differentiation, migration, adhesion and proliferation. Paradoxically, TGF-β also promotes tumor formation, invasion, and metastasis in self-renewing tissues (Abendstein et al., 2000; Abetov et al., 2015). Thus, for some forms of BAVMs, there is evidence for a heritable risk threshold with respect to expressivity and severity of disease. Knowing how TGF-β signaling pathways reflect genetic risk at the level of the patient is necessary to develop a mechanistic understanding of BAVMs.

Pathogenesis and System Genetics

BAVMs are thought to arise between the 4th and 8th week of human embryonic development; however, there is a lack of strong evidence for this tentative hypothesis (Gross et al., 2012; Ieva et al., 2015). In the adult patient, the mean age of diagnosis is ~40 years, but whether older age is associated with increased burden pathology remains to be explored (Gross et al., 2012). Contrary to other vascular pathologies such as arteriovenous fistulas or epidural hematomas, BAVMs are not associated with cranial trauma nor are they linked to any particular environmental risk factor (Gross et al., 2012; Ieva et al., 2015). The etiopathogenesis of BAVMs is therefore not fully understood. However, BAVMs are known to be associated with vascular diseases, such as hereditary hemorrhagic telangiectasia (HHT) and sporadic vascular malformations that cause hemorrhagic strokes and epileptic seizures in young patients (Gross et al., 2012; Ieva et al., 2015; Macellari et al., 2014; Zhou et al., 2016). The fact that most cases of BAVMs are sporadic (≥95%) rather than familial suggests (i) de novo coding mutations that arise in gametes, (ii) single-nucleotide polymorphisms (SNPs) with low penetrance or (iii) rare protein-disrupting mutations might contribute to disorders characterized by the abnormal alignment of endothelial cells. These suggestions blur not only BAVMs origins but also variability of syndromes between patients harboring different forms of somatic mutations. From this perspective, BAVMs are a collection of rare conditions with extensive behavioral heterogeneity and whose symptoms are resistant to specific therapies. This is particularly true for the brain's microvasculature, which is poorly understood at the molecular level, with numerous signaling pathways coordinating early endothelial cell growth, differentiation and proliferation (Zhou et al., 2015, 2016). Finally, it should be noted that at the whole-genome scale, each patient has millions of native intronic variants (Baralle and Baralle, 2005). Many of these variants or haplotypes do not code for proteins but instead regulate gene activity, so they can still contribute to the formation of a high-flow nidus.

Regardless of rates, spectrum and determinants of genomic mutations, BAVMs share common susceptibility loci with HHT. HHT, also known as Osler-Weber-Rendu syndrome, is an autosomal dominant disorder characterized by the presence of vascular malformations in the skin, lung, liver and brain (Gross et al., 2012; Mohl et al., 2013; Goyal et al., 2014; Ieva et al., 2015). Two primary clinical subtypes of HHT are currently clustered. Both subtypes exhibit loss-of-function mutations in genes encoding segments of the transforming growth factor-β (TGF-β) signaling pathway (Fig. 2). For instance, HHT-1 exhibits mutations in endoglin (ENG), which codes for an accessory protein of the TGF-β adaptor complex (Gross et al., 2012; Goyal et al., 2014; Sahlein et al., 2014; Ieva et al., 2015), whereas HHT-2 presents with mutations in activin-like kinase 1 (ALK-1), which codes for a transmembrane-bound kinase receptor associated with the transmission signature of TGF-β (Gross et al., 2012; Goyal et al., 2014; Sahlein et al., 2014; Ieva et al., 2015). TGF-β is a cytokine regulating critical developmental milestones such as cell differentiation, migration, adhesion and proliferation. Paradoxically, TGF-β also promotes tumor formation, invasion, and metastasis in self-renewing tissues (Abendstein et al., 2000; Abetov et al., 2015). Thus, for some forms of BAVMs, there is evidence for a heritable risk threshold with respect to expressivity and severity of disease. Knowing how TGF-β signaling pathways reflect genetic risk at the level of the patient is necessary to develop a mechanistic understanding of BAVMs.

As discussed above, most forms of BAVMs are sporadic (e.g., those observed in a child but not the parents) reflected in patterns of SNPs expressivity within genes encoding pro-inflammatory cytokines such as interleukin-1 β (IL-1 β), tumor necrosis factor-α (TNF-α) and matrix-metalloproteinase (MMPs). The findings that pro-inflammatory cytokines might contribute to nidus
formation in the brain do not yet deliver a complete picture of the genetic landscape of BAVMs. However, there is sufficient information to draw some general conclusions. For instance, pro-inflammatory cytokines might intersect with transcription factors such as the forkhead box O (FOXO1) to adjust vascular density and vascular expansion during specific phases of endothelial cell sprouting (Wilhelm et al., 2016). Indeed, if the activity of FOXO1 is restricted, at least in animal models, it leads to a coordinated reduction in blood vessel branching and blood vessel expansion in mutant retinas (Wilhelm et al., 2016). Furthermore, cerebral cavernous malformations, which are also sporadic in expressivity, appear to arise from endothelial gain of MEKK3-KLF2/4 signaling. Abnormally high levels of this adaptor complex cause specific vascular lesions in mouse and human brains; lesions which are characterized by hemorrhagic dilated venules in the white matter of the cerebellum (Zhou et al., 2016). Against this background, we can begin to formulate the hypothesis that the origin of BAVMs lies in de novo or inherited patterns of transmission, with numerous loss- and gain-of-function signaling pathways interacting broadly with networks of local endothelial molecules to produce a defective vascular phenotype.
Clinical Case Presentation

Because the protein products of genes regulating endothelial cell growth, differentiation, and proliferation often interact with one another, the signaling pathways within them overlap at multiple levels of molecular, cellular, and circuit function. Therefore, it should not be surprising that different gene networks can yield the same clinical phenotype, as seen in BAVMs. Recognition of these signaling pathways has important ramifications for our ability to understand inter-patient heterogeneity. A brief clinical case of BAVM illustrates (i) the heterogeneity of the syndromic presentation, (ii) the overall clinical picture of this rare brain disorder (Box 1) and (iii) the use of structural magnetic resonance imaging (MRI) to decode the surface morphology of arteriovenous lesions (Fig. 3A–C).

Box 1.

A 43-year-old male patient without previous clinical history first presented to the emergency department (ED) with a complaint of “passing out while driving,” giving the impression of a generalized epileptic seizure (Fig. 4A–C). MRI and CAT brain scans revealed a right occipital AVM. The patient returned to the ED at the age of 51, after having a near-syncopal episode. Brain imaging scanning again confirmed the AVM diagnosed 8 years prior. As the patient had no surgical intervention for the BAVM lesions, the immediate treatment was focused on the management of his blood pressure to prevent vessel rupture and minimize the occurrence of ICH.

Common Dimensions of Dysfunction between Brain Arteriovenous Malformations and Anorectal Hemorrhoids

Blood vessels must sprout, elongate, form lumens and regress to adjust their growth state for normal endothelial redox function (Wilhelm et al., 2016). The findings that certain loss- and gain-of-function mutations blunt the growth state of the vascular endothelium suggest that the aforementioned mutations might also contribute...
to similar dimensions of vascular dysfunction outside the brain parenchyma. One area of potential overlap involves the aberrant arteriovenous malformations (AVM) that characterize anorectal hemorrhoids (Sanchez and Chinn, 2011). Although it is not known whether BAVMs and anorectal hemorrhoids share substantial comorbidity or obvious etiology signature, it is interesting that both syndromes share causal signaling pathways of pathogenicity. For example, tissue-specific molecules such as ENG, vascular endothelial-growth factor (VEGF) and MMP-9 are modified in anorectal hemorrhoids (Chung et al., 2004; Lohsiriwat, 2012; Sun and Migaly, 2016); the same molecules that are significantly altered over BAVM-specific background levels. Although, this working hypothesis is coming into focus, interpreting the functional consequences of any of the above signaling pathways to both BAVMs and anorectal hemorrhoids is challenging. The shared signaling pathways currently listed are broad and should be refined at the level of protein function, cellular signaling and tissue domain to determine whether there is unbiased convergence of ENG, VEGF, MMPs, FOXO1, or MEKK3-KLF2/4 signaling contribute to the burden of these diseases. Unfortunately, research on the interactions between independent and overlapping signaling pathways influencing BAVMs and anorectal hemorrhoids is in its earliest stages. Nevertheless, information gained through parallel investigations of BAVMs and anorectal hemorrhoids would be important for the rational development of therapies aimed to correct common elements of arteriovenous dysfunction.

It should be noted that our working hypothesis aims to establish a new framework for brain research that links common signaling dimensions that may be impaired across multiple disorders. In this regard, there is considerable evidence linking type I interferons to psychiatric disorders (Abbott et al., 1987; Angelino and Treisman, 2005; Baraldi et al., 2012), and the pathophysiology of psoriasis and atherosclerosis may be causally linked as proangiogenic factors including interleukin-8 (IL-8), hypoxia inducible factor-1α (HIF-1α), protein C-ETS-1 (ETS-1) and VEGF are implicated in the pathogenesis of both diseases (Christophers, 2007; Armstrong et al., 2011; Eder and Gladman, 2015). Moreover, anorectal dysfunction and constipation are well recognized non-motor symptoms in Parkinson's disease and may reflect the direct involvement of the gastrointestinal tract in response to neuronal damage caused by toxic, aggregation-prone proteins (Barone, 2010; Cloud and Greene, 2011). Thus, for treatment purposes, it is important to know whether BAVMs are solely diseases of the brain, or whether common signaling dimensions of BAVMs also extend to anorectal structures. This information could provide innovative approaches to

| Symptoms:                      | Brain Arteriovenous Malformations | Differential Diagnoses:          |
|--------------------------------|-----------------------------------|----------------------------------|
| Seizures                       | Nidus                             | Cerebral aneurysm                |
| Headaches                      |                                   | Cerebral venous thrombosis       |
| Head pain                      |                                   | Ischemic/ hemorrhagic stroke     |
| Muscle weakness or sensory     |                                   | Intra-cranial hemorrhage         |
| deficit in one area of body    |                                   | Migraine / cluster headache      |
| Complete numbness, weakness,   |                                   | Cavernous sinus syndrome         |
| or paralysis                    |                                   | Subarachnoid hemorrhage          |
| Vision loss                    |                                   | Moyamoya disease                 |
| Difficulty speaking            |                                   | Vein of Galen malformation       |
| Confusion                      |                                   | Carotid/ vertebral artery        |
| Memory lapses                  |                                   | dissection                       |
| Hallucinations                 |                                   | Fibromuscular dysplasia          |
| Unsteadiness                   |                                   | Cerebral amyloid angiopathy      |
| Dementia                       |                                   |                                  |
the management of BAVMs and potentially mitigate the complications suffered by hemorrhoid-prone patients.

**Nutritional Substances in the Treatment of Brain Arteriovenous Malformations and Anorectal Hemorrhoids**

If future studies do implicate overlapping molecular signaling pathways in common dimensions of BAVMs and anorectal hemorrhoids, are there any therapeutic avenues for reducing some of the symptoms associated with arteriovenous dysfunction? From a therapeutic perspective, one potential option is the use of nutritional substances such as dietary fiber which is thought to help stave off maladies ranging from brain disease to intestinal disorders (Zamroziewicz and Barbey, 2016). Indeed, a low fiber diet is commonly assumed to increase the risk of anorectal hemorrhoids (Peery et al., 2015), and conversely, a fiber-enriched diet is the primary treatment option as well as a long-term prophylaxis method for this particular clinical condition (Otles and Ozgoz, 2014). Based upon these observations, can we extrapolate these clinical findings and suggest that consumption of the aforementioned diet might be an effective therapy for BAVMs? Although data still need to be collected, this suggestion may reveal common therapeutics with new potential applications. The onset of age-related diseases such as BAVMs and symptomatic hemorrhoids could benefit from dietary interventions to reduce inflammation which is also a core feature of pathophysiology for both diseases. Along the same lines, a large body of literature exists to support the view that polyphenols such as resveratrol can activate histone deacetylase pathways (e.g., sirtuins) that mechanistically modulate inflammatory conditions (Baur and Sinclair, 2006; Gan and Mucke, 2008; Baur, 2010; Leheste and Torres, 2015). Thus, there are sufficient clinical data to support the hypothesis that BAVMs and anorectal hemorrhoids may favorably respond to high fiber diet and resveratrol treatment protocols. Clinical trials combining all three phases are worth conducting. In this context, the advantages of using fiber, resveratrol or other nutritional interventions are their safety, broad spectrum utility, low costs and apparent suitability for treating clinical conditions that arise as a function of population history and chance.

An extension of nutritional strategies to improve diseases characterized by abnormal dilated arteries and veins, and defined microscopically by the absence of a capillary network, relates to therapeutic solutions that influence gut microbiotic colonization or metabolism. Indeed, targeting the gut microbiota ecosystem to reduce inflammation, high-flow nidus and intermitting bleeding as in BAVMs and anorectal hemorrhoids is of tremendous scientific interest. The emerging insights that the brain and intestinal bacteria intersect to shape neurological and alimentary health could especially be relevant to diseases characterized by vascular dysmorphogenesis (Dinan and Cryan, 2013). As the gut microbiota produces thousands of enzymes that specifically target dietary fiber, resveratrol and complex carbohydrates (Bengmark, 2013; Bode et al., 2013; De Vadder et al., 2014; Claes et al., 2015), it is conceivable that dietary interventions...
that target microorganisms might modulate systemic physiology to reduce the incidence of vessel rupture. Further studies are needed to assess whether manipulation of the gut microbiota is a pragmatic approach to mitigate neurological symptoms that often co-exist with gastrointestinal distress.

CONCLUSION

Together, the previous sections of this review provide a snapshot of BAVMs and their clinical manifestations. We raise the possibility that this particular brain disease has several molecular features in common with gastrointestinal hemorrhoids, and propose that consumption of nutritional substances might lower certain risk thresholds associated with arteriovenous malformation disorders. Because the biology underlying the susceptibility to BAVMs is not clear, the following research questions should further be explored: (i) what are the precise relationship between the disorder and other more tractable pathologies? (ii) How important is diet for minimizing clinical symptoms? And (iv) can the disorder be identified with specific biomarkers to stratify patients for clinical testing?

LITERATURE CITED

Abbott RJ, Bolderson I, Gruer PJ, Peatfield RC. 1987. Immunoreactive IFN-gamma in CSF in neurological disorders. J Neurol Neurosurg Psychiatry 50:882–885.

Abendstein B, Stadlmann S, Knabbe C, Buck M, Müller-Holzner E, Zeimet AG, Marth C, Obriot P, Krugmann J, Offner FA. 2000. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells. Cytokine 12:1115–1119.

Abetov D, Mustapova Z, Saliev T, Bulanin D. 2015. Biomarkers and signaling pathways of colorectal cancer stem cells. Tumour Biol 36:1339–1353. doi: 10.1007/s13277-015-1919-7.

Achrol AS, Guzman R, Varga M, Adler JR, Steinberg GK, Chang SG. 2009. Pathogenesis and radiobiology of brain arteriovenous malformations: Implications for risk stratification in natural history and posttreatment course. Neurosurg Focus 26:E9. doi: 10.3171/2009.4.Essay26.

Angeline AF, Treisman GJ. 2005. Evidence-informed assessment and treatment of depression in HC and interferon-treated patients. Int Rev Psychiatry 17:471–476.

Armstrong AW, Voyles SV, Armstrong Ed, Fuller KN, Rutledge JC. 2011. Angiogenesis and oxidative stress: Common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 62:1–9. doi: 10.1016/j.jdermsci.2011.04.007.

Baralde D, Heguil N, Mondelli V, Pariante CM. 2012. Symptomatic treatment of interferon-α-induced depression in hepatitis C: A systematic review. J Clin Psychopharmacol 32:531–543. doi: 10.1097/CNP.0b013e31825d9892.

Baralle D, Baralle M. 2005. Splicing in action: The in vivo evidence. Nat Rev Drug Discov 5:493–506.

Bengmark S. 2013. Gut microbiota, immune development and function. Pharmacol Res 69:87–113. doi: 10.1016.

Bode LM, Bunzel D, Duch M, Cho GS, Ruhland D, Bunzel M, Bub A, Franz CM, Kulling SE. 2013. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr 97:295–309. doi: 10.3945/ajcn.112.049379.

Christophers E. 2007. Comorbidities in psoriasis. Clin Dermatol 25:338–344.

Chung YC, Hou YC, Pan AC. 2004. Endoglin (CD105) expression in the development of haemorrhoids. Eur J Clin Invest 34:107–112.

Clas IJ, Vargas García CE, Lebeer S. 2015. Novel opportunities for the exploitation of host-microbiome interactions in the intestine. Curr Opin Biotechnol 32:28–34. doi: 10.1016.

Cloud IJ, Greene JJ. 2011. Gastrointestinal features of Parkinson’s disease. Curr Neurol Neurosci Rep 11:379–384. doi: 10.1007/s11910-011-0204-0.

De Vadder F, Kovatcheva-Datchary P, Goncalves D, Virina J, Zitoun C, Duchamp A, Bached K, Mithieux G. 2014. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 156:84–96. doi: 10.1016.

Dinan TG, Cryan JF. 2013. Melanochic microbes: A link between gut microbiota and depression?. Neurogastroenterol Motil 25:715–719. doi: 10.1111/nmo.12198.

Eder L, Gladman DD. 2015. Atherosclerosis in psoriatic disease: Latest evidence and clinical implications. Ther Adv Musculoskelet Dis 7:187–195. doi: 10.17717/15591801.

Friedlander RM. 2007. Arteriovenous malformations of the brain. N Engl J Med 356:2704–2712.

Fullerton HJ, Achrol AS, Johnston C, McCulloch CE, Higashida RT, Lawton MT, Sidney S, Young WL. 2005. Long-term hemorrhage risk in children versus adults with brain arteriovenous malformations. Stroke 36:2099–2104.

Gan L, Macke L. 2008. Paths of convergence: Sirtuins in aging and neurodegeneration. Neuron 58:10–14. doi: 10.1016/j.neuron.2008.03.015.

Goyal N, Hoit D, Elizovich L. 2014. Spontaneous thrombosis of a ruptures brain arteriovascular malformation: the argument for early conservative management. Interv Neurol 3:122–128. doi: 10.1509/

Gross B, Frerichs KU, Du R. 2012. Sensitivity of CT angiography, T2-weighted MRI, and magnetic resonance angiography in detecting cerebral arteriovenous malformations and associated aneurysms. J Clin Neurosci 19:1093–1095. doi: 10.1016/j.jocn.2011.11.021.

Ieva AD, Boukdadoum M, Lahmiri S, Cusimano MD. 2015. Computational analyses of arteriovenous malformations in neuroimaging. J Neuroimaging 25:354–360. doi: 10.1111/jon.12200.

Leheste JR, Torres G. 2015. Resveratrol: Brain effects on SIRT1, GPR50 and photoperiodic signaling. Front Mol Neurosci 8:doi: 10.3389/fnmol.2015.00061.

Lohsirivat W. 2012. Hemorrhoids: From basic pathophysiology to clinical management. World J Gastroenterol 18:2009–2017. doi: 10.3748/wjg.v18i17.2009.

Macellari F, Faciaroni M, Agnelli G, Caso V. 2014. Neuroimaging in intracerebral hemorrhage. Stroke 45:909–908. doi: 10.1161/STROKEAHA.114.003906.

Mehl J, Keja-Scharler J, Pile-Spellman J. 2013. Diagnosis and treatment of arteriovenous malformations. Curr Neurol Neurosci Rep 13:1–7. doi: 10.1007/s11910-012-0324-1.

Otles S, Ozgoz S. 2014. Health effects of dietary fiber. Acta Sci Pol Technol Aliment 13:191–202.

Peery AF, Sandler RS, Galanko JA, Bressler RS, Figueiredo JC, Akhen DJ, Barry EL, Baron JA. 2015. Risk factors for hemorrhoids on screening colonoscopy. PLoS One 10:e0139100. doi: 10.1371/journal.pone.0139100.

Sahlein DH, Mora P, Becske T, Huang P, Jafar JJ, Connolly S, di Meglio P, Sahlein DH, Mora P, Becske T, Huang P, Jafar JJ, Connolly S, di Meglio P. 2014. Health effects of dietary fiber. Acta Sci Pol Technol Aliment 13:191–202.

Sun Z, Migaly J. 2016. Review of hemorrhoid disease: Presentation and management. Clin Colon Rectal Surg 29:22–29. doi: 10.1055/

Van Beijnum J, van der Worp HB, Schippers HM, van Nieuwenhuizen O, Kappelle LJ, Rinkel GJ, Berkelbach van der Sprenkel JW, Klijn CJM. 2007. Familial occurrence of brain arteriovenous malformation hemorrhage exploration to a physiologic model. Stroke 45:1964–1970.

Sanchez C, Chinn BT. 2011. Hemorrhoids. Clin Colon Rectal Surg 24:5–13. doi: 10.1055/s-0031-1272818.

Zimmermann B, Aspalter IM, Franco CA, Boettger T, et al. 2016.
FOXO1 couples metabolic activity and growth state in vascular endothelium. Nature 529:216–220. doi: 10.1038/nature16498.

Zamroziewicz MK, Barbey AK. 2016. Nutritional cognitive neuroscience: Innovations for healthy brain aging. Front Neurosci. 10:240. https://doi.org/10.3389/fnins.00240.

Zhou Z, Rawnsley DR, Goddard LM, Pan W, Cao XJ, Jakus Z, Zheng H, Yang J, Arthur JS, Whitehead KJ, et al. 2015. The cerebral cavernous malformation pathway controls cardiac development via regulation of endocardial MEKK3 signaling and KLF expression. Dev Cell 32:168–180. doi: 10.1016.

Zhou Z, Tang AT, Wong WY, Bamezai S, Goddard LM, Shenkar R, Zhou S, Yang J, Wright AC, Foley M, etal. 2016. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature 532:122–126. doi: 10.1038/nature17178.